Clinical significance of p53 alterations in surgically treated prostate cancers

[1]  Magdi Kirollos,et al.  Re: Axel Heidenreich, Gunnar Aus, Michel Bolla, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80. , 2008, European urology.

[2]  J. Gregg,et al.  Profiling of gene expression changes caused by p53 gain‐of‐function mutant alleles in prostate cancer cells , 2005, The Prostate.

[3]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[4]  L. Bubendorf,et al.  Expression patterns of potential therapeutic targets in prostate cancer , 2005, International journal of cancer.

[5]  G. Viale,et al.  The clinical significance of p53 aberrations in human tumours , 2004, Virchows Archiv.

[6]  Ronald Simon,et al.  Tissue microarrays in drug discovery , 2003, Nature Reviews Drug Discovery.

[7]  M. Graefen,et al.  Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy , 2003, Journal of Cancer Research and Clinical Oncology.

[8]  R. deVere White,et al.  Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. , 2003, Cancer research.

[9]  W. Zhang,et al.  p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein , 2003, Prostate Cancer and Prostatic Diseases.

[10]  A. Giordano,et al.  Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  K. Pienta,et al.  Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.

[12]  M. Graefen,et al.  Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. , 2002, European urology.

[13]  C. Abbou,et al.  EAU guidelines on prostate cancer. , 2009, European urology.

[14]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[15]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[16]  J. Overgaard,et al.  p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. , 2000, The Journal of urology.

[17]  J. Wilson,et al.  Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. , 2000, Cancer research.

[18]  John T. Wei,et al.  BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. , 1999, The Journal of urology.

[19]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[20]  M. Rubenstein,et al.  An evaluation of the markers p53 and Ki‐67 for their predictive value in prostate cancer , 1998, Journal of surgical oncology.

[21]  M. Kattan,et al.  Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. , 1998, Cancer.

[22]  L. Cox.  Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1 , 1997, The Journal of pathology.

[23]  R. Cote,et al.  p53 protein and gene alterations in pathological stage C prostate carcinoma. , 1997, The Journal of urology.

[24]  D. Grignon,et al.  p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. , 1997, Journal of the National Cancer Institute.

[25]  J. Brooks,et al.  An uncertain role for p53 gene alterations in human prostate cancers. , 1996, Cancer research.

[26]  J. Moul,et al.  p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  H. Huland,et al.  Immunohistochemical detection of p53 protein in human prostatic cancer. , 1994, The Journal of urology.

[28]  W. W. Nichols,et al.  p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.

[29]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[30]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.